interferon gamma

November 6, 2017November 6, 2017

CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies

News

CBT Pharmaceuticals‘ anti-PD-L1 antibody CBT-502 has shown promising immune activation and inhibition of tumor growth in preclinical models of cancer, according to new preclinical data. The data were presented in ... Read more

June 5, 2017June 5, 2017

Genome Profiling May Help Predict Response to Keytruda in Head-Neck Cancer Patients

News

Profiling the genome of patients with head and neck squamous cell carcinoma (HNSCC) for mutations and interferon (IFN)-gamma-induced gene expression may independently predict patients’ response to immunotherapy with Keytruda (pembrolizumab), ... Read more

October 25, 2016

Study Shows How Cancer Cells Evade Immunotherapy, Help Select Better Treatment Targets

News

Researchers have discovered a novel mechanism by which tumor cells evade adoptive T-cell therapies — immunotherapies that use a patient’s own blood cells — which may help identify novel, more suitable targets for ... Read more

February 10, 2016February 10, 2016

Cancer Immunotherapy Study Tips Immune System to Favor Tumor-Fighting Cells

News

Researchers may have taken a possibly important step in advancing cancer immunotherapy by successfully altering pro-tumor immune cells to become tumor-fighting immune cells. Their paper, titled “A Breakthrough: Macrophage-Directed Cancer Immunotherapy,” was published ... Read more

August 11, 2015August 11, 2015

Horizon Pharma and Fox Chase Cancer Center Partner to Study ACTIMMUNE Combined With PD-1/PD-L1 Inhibitors in Cancer

News

Horizon Pharma plc, a biopharmaceutical company dedicated to identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, has just announced it entered a collaborative agreement with Fox Chase ... Read more